A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance.

An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair genes.

The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy that blocks cancer cells from repairing their DNA when damaged - alongside the standard abiraterone acetate and prednisone treatments.

Patients with a certain form of aggressive prostate cancer could benefit from a new combination of drugs which slow cancer growth, according to a new study.